Traders Purchase High Volume of Mural Oncology Put Options (NASDAQ:MURA)

Mural Oncology plc (NASDAQ:MURA) was the recipient of unusually large options trading activity on Tuesday. Stock traders purchased 27,546 put options on the stock. This represents an increase of approximately 15,731% compared to the typical volume of 174 put options.

Mural Oncology Trading Up 147.6 %

Shares of Mural Oncology stock traded up $1.52 during trading on Tuesday, hitting $2.55. 247,403,397 shares of the stock traded hands, compared to its average volume of 1,175,492. Mural Oncology has a 52-week low of $0.95 and a 52-week high of $4.74. The stock’s fifty day simple moving average is $3.01 and its 200 day simple moving average is $3.38. The firm has a market cap of $43.93 million, a P/E ratio of -0.28 and a beta of 5.28.

Mural Oncology (NASDAQ:MURA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) EPS for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same quarter last year, the company posted ($3.57) EPS. As a group, equities analysts expect that Mural Oncology will post -7.54 EPS for the current year.

Institutional Trading of Mural Oncology

A number of hedge funds have recently bought and sold shares of the stock. Acorn Capital Advisors LLC bought a new position in shares of Mural Oncology in the 4th quarter worth $4,141,000. Raymond James Financial Inc. purchased a new stake in shares of Mural Oncology during the fourth quarter valued at about $181,000. Virtu Financial LLC bought a new stake in shares of Mural Oncology in the 4th quarter valued at about $129,000. Renaissance Technologies LLC boosted its holdings in shares of Mural Oncology by 17.4% in the 4th quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock valued at $768,000 after buying an additional 35,403 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Mural Oncology in the 4th quarter worth approximately $94,000. Hedge funds and other institutional investors own 80.21% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on MURA shares. Jones Trading reissued a “hold” rating on shares of Mural Oncology in a research report on Tuesday, March 25th. Raymond James downgraded Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price target on the stock. in a report on Tuesday, March 25th. Morgan Stanley cut Mural Oncology from an “overweight” rating to an “equal weight” rating in a report on Tuesday, March 25th. Finally, HC Wainwright reduced their target price on Mural Oncology from $18.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, March 26th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Mural Oncology currently has an average rating of “Moderate Buy” and an average price target of $13.00.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.